TSH from human serum was separated into classes by serial lectin affinity chromatography using Concanavalin-A (ConA), lentil, and ricin lectins. TSH from 10 euthyroid subjects, 40 patients with primary hypothyroidism, and 1 patient with central hypothyroidism was studied. The patterns of ConA and lentil affinity binding were similar for diverse patients; forms of TSH that bound firmly to ConA also tended to bind firmly to lentil. Differences in TSH-ricin binding suggested that there were differences in the sialylation of TSH in sera of euthyroid, primary, and central hypothyroidism patients. For euthyroid subjects, 16.1 +/- 5.4% (mean +/- SD) of the TSH bound to ricin, while after neuraminidase treatment, 38.4 +/- 5.4% bound. For patients with primary hypothyroidism, 23.5 +/- 6.0% of the TSH bound to the ricin, while after neuraminidase treatment, 65.7 +/- 8.8% bound. The increase in ricin binding induced by neuraminidase treatment was significantly higher for TSH from patients with primary hypothyroidism than in that from euthyroid subjects (42.3 +/- 7.6% vs. 22.3 +/- 4.4%; P less than 0.01) and was greater for long term than for short term hypothyroid patients (49.5 +/- 5.0% vs. 36.5 +/- 6.5%; P less than 0.01). While 30% of native TSH from the serum of the patient with central hypothyroidism bound to ricin, the amount bound increased only 17.6% after neuraminidase treatment. McKenzie bioassay of pituitary-derived TSH that was similarly fractionated using ricin failed to show detectable differences in bioactivity among the lectin column fractions. Thus, 1) circulating human TSH can be consistently separated into discrete classes using serial lectin affinity chromatography; 2) there is relatively more core fucosylation of the less processed high mannose and hybrid forms of TSH and less core fucosylation of more processed complex forms; 3) ConA and lentil binding of TSH in primary and central hypothyroidism is similar to that in the euthyroid state; 4) patients with primary hypothyroidism have more sialylated TSH than a patient with central hypothyroidism or euthyroid subjects; and 5) the degree of TSH sialylation increases with prolonged primary hypothyroidism.
We have studied the effects of Brefeldin-A (BFA) on the processing of high mannose (Man) oligosaccharides of TSH. BFA is a drug that inhibits the intracellular translocation of newly synthesized glycoproteins and causes dilatation of the rough endoplasmic reticulum (RER) as well as mild swelling of the Golgi apparatus. Mouse pituitary thyrotropic tumor tissue was incubated with [3H]Man for a 2-h pulse, with and without a 3-h chase; BFA (5 micrograms/ml) was included during selected pulse and selected chase incubations. TSH and free alpha-subunits were obtained from detergent lysates of tissue by immunoprecipitation using specific antisera. Total glycoproteins were obtained by trichloroacetic acid precipitation. Endoglycosidase-H-released [3H]oligosaccharides were analyzed by paper chromatography. BFA inhibited carbohydrate processing of TSH, free alpha-subunits, and total glycoproteins, resulting in the accumulation of Man8GlcNAc2, Man7GlcNAc2, Man6GlcNAc2, and Man5GlcNAc2, especially during the chase period. Subcellular fractions enriched in RER, heavy (proximal) Golgi, and light (distal) Golgi were prepared by centrifugation in discontinuous sucrose gradients. [3H]Man-labeled oligosaccharides of TSH and total glycoproteins in the subcellular fractions were analyzed. In contrast to oligosaccharides with eight or nine Man residues found in control incubations, BFA caused the accumulation of oligosaccharides containing five to eight Man residues. These BFA-induced oligosaccharide alterations began in the RER and proximal Golgi with the 2-h pulse and extended into the distal Golgi during the chase incubations. Thus, BFA blocks the normal intracellular transport and processing of TSH, free alpha-subunits, and total glycoproteins within thyrotrophs, causing species with smaller than normal high Man oligosaccharides to appear in subcellular compartments as early as the RER. The translocation block between RER and Golgi produced by BFA may prevent the processing of Man8GlcNAc2 to Man5GlcNAc2 by Golgi (alpha,1-2)mannosidase I, yet the species retained within the RER may be subject to ongoing processing by endoplasmic reticulum (alpha,1-2)mannosidase, resulting in the accumulation of Man5-8GlcNAc2 within the RER.
Insulin-like growth factor binding proteins (IGFBPs), are produced by several cell types, are present in biological fluids, and may function in modulating insulin-like growth factor (IGF) biological activities. Recently the presence of multiple IGFBPs was reported in seminal fluid, suggesting that IGFBPs are produced by prostatic epithelium. We have found that human prostatic tumor cells of the PC3 cell line produce an IGFBP. PC3-IGFBP was purified to homogeneity using sequential IGF I affinity and HPLC C4 reverse phase chromatographies. Chemical cross-linking of PC3-IGFBP to 125I-IGF I revealed a molecular weight of 25 kDa. Its N-terminal sequence and amino-acid composition were highly homologous to that of a recently described 25 kDa inhibitory IGFBP (In-IGFBP), produced by osteoblasts in vitro. PC3-IGFBP inhibited basal and IGF II-stimulated bone cell DNA synthesis. We conclude that the PC3-IGFBP is very similar, if not identical to the osteoblast-derived In-IGFBP. Expression of PC3-IGFBP by metastatic human prostate tumor cells thus might affect the osteoblast proliferation that is induced by metastatic prostatic carcinoma. The PC3-IGFBP may be similar to a 24 kDa IGFBP described in seminal fluid and thus may be important in the regulation of cell proliferation in the male reproductive tract.
To determine if there is a familial component to susceptibility to radiation-induced thyroid neoplasms, we studied 572 individuals who were members of 286 sibpairs who received childhood radiation treatment and for whom follow-up information was obtained. Of these 572 individuals, 240 (42.0%) had thyroid neoplasms (benign and malignant), and 75 (13.1%) had surgically confirmed thyroid cancer. To test the null hypothesis, that neoplasm occurred without regard to family membership, it was necessary to take into account each individual's years at risk and known risk factors. These risk factors, analyzed by the proportional hazards model of Cox, were sex, age at time of radiation treatment, and treatment dose. For each individual, we calculated the cumulative hazard that a neoplasm would occur from that individual's specific risk factors and years at risk. Each individual was also assigned an indicator, D = 1 or 0, according to whether a neoplasm had occurred. Finally, for each individual we computed a residual, D minus the cumulative hazard. In the absence of familial effects, positive and negative residuals would be distributed without regard to family membership, whereas residuals would tend to have concordant signs and magnitudes within families if familial effects were present. Permutational methods, therefore, were used to determine whether the sum among families of the products of residuals within sibpairs was too large, compared to random pairing. For all thyroid neoplasms (both benign and malignant), within-family concordance was significant (P = 0.05, the observed sum among families of the products of residuals was larger than 9468 of 9999 permutations). For thyroid cancer considered alone, the same analysis did not demonstrate familial concordance conclusively, but the results were suggestive (P = 0.18). We conclude that in addition to the previously described risk factors of female sex, younger age at radiation exposure, and higher dose, it is likely that there are independent familial risk factors for developing thyroid neoplasms. Whether these are genetic or environmental factors remains to be determined.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.